🧬🚀 Biotech VC @ https://xitter.cf/t.co/7fUi8JnEvT Breakout Fund.👨🔬Biological Engineering PhD @MIT. 🙆♂️ Fmr performer/director @improvboston. he/him. 🌶 Hot takes are my own
Cambridge, MA
Joined December 2011
- Tweets434
- Following343
- Followers909
- Likes2.9K
Grateful to be part of the "Survivor Tribal Council" of Academy Members for this year's NEVY awards in Life Sciences! Excited for the companies that were selected - hope you can join us to see the winners announced on December 5th! @NewEnglandVC bit.ly/academies24
So much of scientific research is focused on bringing science fiction to life. It’s amazing how many of our most important innovations first came from the minds of writers
This robot is alive. Incorporated into its electronics are living fungal tissues that change the robot's behavior when exposed to intense light. That and more of the best from @ScienceMagazine and science in this edition of #ScienceAdviser: science.org/content/article/…
Great examples of why first in class and best in class are so important in our industry - there are very few drugs that win on a given mechanism, in many cases just 1.
A ton of capital being spent developing insufficiently differentiated products that are perceived as “low risk”
What's driving that bimodal distribution? Differentiation, or lack thereof
Order of entry is incredibly important for undifferentiated drugs. Conversely, it plays a far lesser role for differentiated products. In both cases, avg. benchmarks under / overstate potl. share (3/4)
ALT https://www.lek.com/sites/default/files/PDFs/best-class-biopharma.pdf
ALT https://www.lek.com/sites/default/files/PDFs/best-class-biopharma.pdf
Devin Quinlan retweeted
The disruptive potential for gene and cell therapies is taking center stage in the biotech business
@ElevateBio CEO & Chairman David Hallal talks his company's mission, the road ahead, and the potential impact these therapies could have on patients:
Congrats to our new company Reunion Neuroscience on a $103M Series A! Reunion is a clinical-stage company developing novel psychedelic therapies for postpartum depression!
endpts.com/a-once-public-psy…
What a headline! Brought me back to AP Bio. Also - a very accurate takeaway from this year's AACR. @BioCentury
Devin Quinlan retweeted
J&J’s William Hait highlighting the burden on pharma to launch products : 40 phase 1 ➡️ 3 BLAs! Hence $2B+ per drug launched. #AACR24 “Path to Entrepreneurship” session
Great writeup on DACs from @BioCentury! Lot of potential combinations of targets and payloads - looking forward to seeing the field evolve 🚀
biocentury.com/article/65188…
Devin Quinlan retweeted
Company News: Nobel laureate @CarolynBertozzi on the launch of Firefly Bio and the science of degrader antibody conjugates.
Full video: biotechtv.com/post/firefly-b…
Excited to announce our newest portfolio company - Firefly Bio! Debuting with $94M, Firefly is pioneering degrader-antibody conjugates as an evolution to ADCs. MPM co-led the Series A financing with Versant Ventures, alongside Decheng and Lilly
fireflybiologics.com/press-r…
28% reduction in rate of heart attacks and 19% reduction in all-cause death for patients in this trial taking wegovy 🤯
BREAKING --> Wegovy cuts risk of heart attacks in milestone cardiovascular trial statnews.com/2023/11/11/hear… via @elaineywchen $NVO $LLY #AHA23
Devin Quinlan retweeted
MPM BioImpact is pleased to participate in the Series A financing of AstronauTx to develop novel treatments for Alzheimer’s disease and other neurodegenerative disorders. Read the press release: astronautx.bio/astronautx-cl…
Nice article in @BioCentury on circular RNA - featuring our own @orna_tx!
biocentury.com/article/64880…
It depends on your definition of bioengineering. Protein engineering, syn bio, gene editing are all making major breakthroughs.
Using engineering principles to predict/model biology is limited by the quality of the measurements we can take and translatability of the assays
Congrats to Crossbow Therapeutics on the launch and $80M Series A! Inspired by the success of KIMMTRAK, Crossbow was founded by @MPMCapital to pioneer TCR-mimetic antibodies to tackle intracellular tumor antigens!
biospace.com/article/release…
Thanks to @MassBio for having me in a panel this morning discussing the investment climate and it's impact on biotech decisionmaking!
VOD: youtube.com/watch?v=GE3Xc5i8…
Grateful to see this (finally) come out! Hope Ram can find peace & move forward
statnews.com/2023/06/14/ram-…
Scientific dishonesty is tricky to untangle, but ultimately the responsibility lies with management, especially CEO & CSO. Culture emanates from the top down and pressure to produce results creates conflicting incentives.
Sprint at the killer experiments, don't avoid them
Devin Quinlan retweeted
Thank you to Brian Goodman and @devinquinlan at @MPMCapital for hosting the Harvard Biotech Club Pitch Deck Creation Workshop of the Engage series! Students learned the essential elements of a compelling pitch deck and presented their business ideas to MPM employees for feedback.
